Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2019

Feb 14, 2020

SELL
$37.13 - $74.62 $2.04 Million - $4.1 Million
-55,000 Reduced 64.71%
30,000 $2.15 Million
Q2 2019

Aug 14, 2019

BUY
$52.76 - $82.19 $4.48 Million - $6.99 Million
85,000 New
85,000 $6.99 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $280M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.